Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma : a single-center cross-sectional study
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: Bortezomib is a neurotoxic drug used in multiple myeloma and responsible for chemotherapy-induced peripheral neuropathy (CIPN). In a previous cross-sectional study, CIPN prevalence was about 26.9% in 67 patients. A second data analysis was performed to explore the relation between CIPN and auditory difficulties.
METHODS: Based on 66 multiple myeloma patients from a single center, auditory difficulties were assessed with a self-questionnaire and compared to sensory CIPN (QLQ-CIPN20 questionnaire), patients' characteristics and anticancer treatments.
RESULTS: The prevalence of auditory difficulties was about 42.4% (95% CI [30.6-55.2]) of the 66 patients analyzed and was higher in patients with CIPN than without (82.4% vs. 28.6%, p < 0.001). Auditory difficulties were not related to the characteristics of patients and treatments. The severity of auditory difficulties were correlated to CIPN severity (spearman's coefficient: 0.49, p = 0.009). Odds-ratio of auditory difficulties (multivariable analysis adjusted for sensory CIPN, recreation or professional noise exposure, gender, age, and treatments) was significantly associated with CIPN (18.7, 95% CI [3.0-117.1], p = 0.002).
CONCLUSION: This relation between CIPN and auditory difficulties raises concerns about hearing safety in multiple myeloma patients treated by bortezomib.
TRIAL REGISTRATION NUMBER: NCT03344328.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:279 |
|---|---|
| Enthalten in: |
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery - 279(2022), 4 vom: 08. Apr., Seite 2197-2201 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giraudet, Fabrice [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
69G8BD63PP |
|---|
| Anmerkungen: |
Date Completed 21.03.2022 Date Revised 31.05.2022 published: Print-Electronic ClinicalTrials.gov: NCT03344328 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00405-021-07234-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336320906 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336320906 | ||
| 003 | DE-627 | ||
| 005 | 20231225231859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00405-021-07234-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336320906 | ||
| 035 | |a (NLM)35098333 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giraudet, Fabrice |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma |b a single-center cross-sectional study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03344328 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: Bortezomib is a neurotoxic drug used in multiple myeloma and responsible for chemotherapy-induced peripheral neuropathy (CIPN). In a previous cross-sectional study, CIPN prevalence was about 26.9% in 67 patients. A second data analysis was performed to explore the relation between CIPN and auditory difficulties | ||
| 520 | |a METHODS: Based on 66 multiple myeloma patients from a single center, auditory difficulties were assessed with a self-questionnaire and compared to sensory CIPN (QLQ-CIPN20 questionnaire), patients' characteristics and anticancer treatments | ||
| 520 | |a RESULTS: The prevalence of auditory difficulties was about 42.4% (95% CI [30.6-55.2]) of the 66 patients analyzed and was higher in patients with CIPN than without (82.4% vs. 28.6%, p < 0.001). Auditory difficulties were not related to the characteristics of patients and treatments. The severity of auditory difficulties were correlated to CIPN severity (spearman's coefficient: 0.49, p = 0.009). Odds-ratio of auditory difficulties (multivariable analysis adjusted for sensory CIPN, recreation or professional noise exposure, gender, age, and treatments) was significantly associated with CIPN (18.7, 95% CI [3.0-117.1], p = 0.002) | ||
| 520 | |a CONCLUSION: This relation between CIPN and auditory difficulties raises concerns about hearing safety in multiple myeloma patients treated by bortezomib | ||
| 520 | |a TRIAL REGISTRATION NUMBER: NCT03344328 | ||
| 650 | 4 | |a Clinical Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bortezomib | |
| 650 | 4 | |a Chemotherapy-induced peripheral neuropathy | |
| 650 | 4 | |a Hearing disorders | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 700 | 1 | |a Selvy, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Kerckhove, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Barreau, Fantine |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Busserolles, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrespine, Aurélie |e verfasserin |4 aut | |
| 700 | 1 | |a Chaleteix, Carine |e verfasserin |4 aut | |
| 700 | 1 | |a Soubrier, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Bay, Jacques-Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Lemal, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Balayssac, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery |d 1994 |g 279(2022), 4 vom: 08. Apr., Seite 2197-2201 |w (DE-627)NLM012637548 |x 1434-4726 |7 nnns |
| 773 | 1 | 8 | |g volume:279 |g year:2022 |g number:4 |g day:08 |g month:04 |g pages:2197-2201 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00405-021-07234-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 279 |j 2022 |e 4 |b 08 |c 04 |h 2197-2201 | ||